| PyloriMed |
Phase 2 ready for H Pylori eradication, GERD
H Pylori strongly linked to chronic active gastritis, peptic ulcer, atrophic gastritis, MALT lymphoma and gastric cancer .
Eradication limited by antibiotic resistance, suboptimal acid suppression and pill burden leading to poor compliance.
* Pylori Med’s novel CMA-PPI H. pylori eradication regimen combines long-duration pro-omeprazole with amoxicillin
* Phase 2 ready with established CMC methods and more than sufficient intermediate for Phase 2
Good market potential with 3 million prescriptions in US for PPI plus antibiotic in 2016.
Huge Upside in nighttime acid breakthru GERD
| 新型CMA-PPI制剂
幽门螺旋杆菌根除综合解决方案。
目前研发进度已经到临床二期。
研究表明，幽门螺杆菌与慢性活动性胃炎、消化性溃疡、萎缩性胃炎、MALT淋巴瘤和胃癌密切相关。
但幽门螺杆菌的根除受限于抗生素耐药性，抑制胃酸不理想和药物负担等问题，效果不理想。
我们的新产品针对上述痛点，结合了长效的奥美拉唑和阿莫西林，为幽门螺杆菌的治疗提出了新型的治疗解决方案。
产品优势：
*已通过成熟的CMC方法，并提供了足够的中间体，为临床2期做好准备。
*良好的市场潜力，2016年在美国有300万张PPI加抗生素处方。
*对于GRED，夜间酸突破方面能带来巨大的好处。
|
| ABCENTRA |
Phase 2 Ab to oxLDL
Orticumab - Anti-inflammatory monoclonal antibodies targeting oxidized low-density lipoprotein (oxLDL).
Preparing for Phase II
*260 patients have been treated with excellent safety profile through 3 clinical trials.
*Possible indications include: atherosclerosis, psoriasis.
| 泰凌医药(01011.HK)发布公告，于2022年6月21日，被许可方Green-Life Technology (Hong Kong) CompanyLimited（公司全资附属公司）与许可方Abcentra LLC订立许可及合作协议，据此，许可方有条件同意不可撤销地授予被许可方许可，即于中国、香港、澳门、台湾、新加坡、马来西亚及泰国等地区将该技术商业化的独家永久许可。
|
| APTITUDE VISION |
VEGF/ang2 bispecific aptamer for ophthalmology
Standard of care anti-VEGF has limited efficacy and frequent injections
* Aptitude's aptamer has added efficacy from ang2
* And 10x greater VEGF potency and 100x greater ang2 potency than Roche Faricimab
* And much longer duration
These combine to mean MUCH longer time over minimal effective concentration = LESS FREQUENT DOSING
|
眼科用VEGF / ang2双特异性抗体
抗VEGF的护理标准疗效有限且经常注射
* Aptitude的适体增加了ang2的功效
*与Roche Faricimab相比，VEGF效能高10倍，ang2效能高100倍
*持续时间更长
这些结合在一起意味着在最小有效浓度下需要更长的时间=更少的剂量
|
| BridGene Biosciences |
With a platform with covalent inhibitors to 5000 targets, BridGene can collaborate to
* identify a hit for a hard to drug-like hit target and provide information on selectivity to enable a rapid creation of a lead candidate
* identify the targets of phenotypic screens
Two covalent inhibitors programs ready for partnering
FGFR4 inhibitor for cancer:
* small molecule with oral bioavailability,
* efficacy and regression in HCC and Rhabdomyosarcoma models
* great selectivity
* inhibition of gatekeeper mutations
GMPS inhibitor for lupus and other autoimmune disorders:
Novel immunosupressant
GMPS is downstream of IMPDH in purine synthesis where approved MPA (MMF) immunosuppressant acts
* nM potency
* suppression of T cell activation and T cell growth
* In vivo effects
|
带有共价抑制剂的平台借助具有针对5000个靶标的共价抑制剂的平台，BridGene可以与
*确定难以被药物针对的目标，并提供有关选择性的信息，以快速创建潜在候选化合物
*确定表型筛选的目标
两个共价抑制剂计划准备合作
1. FGFR4癌症抑制剂：
*具有口服生物利用度的小分子，
*在HCC和横纹肌肉瘤模型中的疗效和消退
*极大的选择性 *抑制网守突变
2. GMPS狼疮和其他自身免疫性疾病的抑制剂：新型免疫抑制剂
GMPS在嘌呤合成中IMPDH的下游，其中批准的MPA（MMF）免疫抑制剂起作用
* nM有效剂量， 抑制T细胞活化和T细胞生长*体内作用
|
| GLYCONEX |
A humanized IgG antibody GNX102 for cancer in Phase 1 in US and Taiwan.
* Targeted to biantennary LeY to target many cancers with higher selectivity versus normal cells.
* GNX102 showed great anti-tumor efficacy in human tumor xenograft models.
* Pilot toxicology studies showed that GNX102 was well tolerated in tested rats, dogs, and Cynomolgus monkeys.
* GNX102 showed superior safety profile in GLP tox studies in rat and Cynomolgus monkeys.
|
一种在美国和台湾用于1期临床治疗癌症的人源化IgG抗体GNX102。
*针对双天线LeY，以比正常细胞更高的选择性靶向许多癌症。
* GNX102在人类肿瘤异种移植模型中显示出出色的抗肿瘤功效。
*初步毒理学研究表明，GNX102在测试的大鼠，狗和食蟹猴中具有良好的耐受性。
* GNX102在大鼠和食蟹猴的GLP毒理研究中显示出优异的安全性。
|
| LOKI THERAPEUTICS |
Breakthrough cancer immunotherapy with antigens of childhood vaccination
* Activates and redirects pre-existing memory T cells created during childhood tetanus vaccination to solid tumors and metastases
* Attenuated Listeria infects tumor homing MDSC to deliver the antigens to the tumors
* Unlike many approaches where converting naive T cells to memory T cells is hard in older patients
* Antigens very immunogenic and not subject to tumor mutagenesis
|
采用儿童接种抗原的突破性癌症免疫疗法
*激活并重定向在儿童破伤风疫苗接种过程中产生的先前存在的记忆T细胞，使其转移至实体瘤和转移灶
*减毒李斯特菌感染肿瘤归巢MDSC，将抗原传递给肿瘤
*与许多在老年患者中很难将幼稚T细胞转化为记忆T细胞的方法不同
*抗原具有很高的免疫原性，不会引起肿瘤诱变
|
| EXTEND BIO |
Peptide therapeutics with extended duration and subcutaneous bioavailability
* Long-acting grelin derivative for cancer cachexia - a single dose reverses cachexia in animal models
* Long-acting PTH for hypoparathyroidism
|
具有更长持续时间和皮下生物利用度的多肽治疗剂
*长效Grelin衍生物可治疗癌症恶病质-单剂量可逆转动物模型中的恶病质
*长效甲状旁腺激素可治疗甲状旁腺功能低下
|
| Sound Biologics |
Pair of Abs from a single cell to be a single drug entity, allowing different isotypes and stoichiometries, for rapid product creation
* In Phase 1: PSB205: PD1 and CTLA4 Abs from a single cell designed to have rapid clearance of the CTLA4 for optimal efficacy
* Multiple IO candidates including PD1/x, CD20/CD37 pair, Her2/Her2 pair
* Also seeking partnerships on platform
|
一对来自单个细胞的抗体成为一个单一的药物实体，允许不同的同种型和化学计量比，以快速创建产品
*临床1期：PSB205：来自单个细胞的PD1和CTLA4抗体设计用于快速清除CTLA4，以实现最佳功效
*多个肿瘤免疫候选项目，包括PD1 / x，CD20 / CD37对，Her2 / Her2
*此平台寻求合作伙伴
|
| Glyconex |
well characterized biosimilar to denosumab for osteoporosis and bone metastases from multiple myeloma
* 200L scale with cell line
* Great comparability and stability
|
与地诺单抗相似的生物仿制药，用于治疗多发性骨髓瘤的骨质疏松和骨转移
* 200L规模细胞株
*出色的可比性和稳定性
|